Application for patents with the title of “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” are waiting for approval in Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Ireland, Italy, Korea, Luxembourg, Mexico, Monaco, New Zealand, Norway, Singapore, Spain, Sweden, Switzerland, The Netherlands, Turkey, United Kingdom, and United States of America.